Prevention of Progression in Chronic Liver Disease

An Update on SNMC (Stronger Neo-Minophagen C). In honour of Hans Popper's 100th birthday
2004
ISBN: 978-0-7923-8796-1
Verlag: Springer Netherlands

Buch, Englisch, Band 138A, 130 Seiten, HC runder Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 383 g

Reihe: Falk Symposium

In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.

Zielgruppe

Research

Autoren/Hrsg.

Manns, M. P.

Hiyashi, N.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Präventivmedizin, Gesundheitsförderung, Medizinisches Screening
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Hepatologie

Inhaltsverzeichnis

List of Principal Authors.- Preface. Introduction.- 1: Mechanisms of fibrogenesis.- 2: Non-invasive markers of liver injury.- 3: Complications of cirrhosis: the relevance of hepatocellular carcinoma.- 4: Controlling necroinflammation of liver with SNMC (Stronger Neo Minophagen C): therapy on interferon non-responders.- 5: Predictive parameters of non-response to standard hepatitis treatment.- 6: Concepts for the treatment of non-responders in hepatitis.- 7: Glycyrrhizin: the molecule and present knowledge of action in various liver diseases.- 8: Dendritic cells in immune responses against hepatitis C virus.- 9: SNMC in the prevention of cirrhosis and hepatocellular carcinoma: Japanese experience.- 10: SNMC in interferon non-responders with chronic hepatitis C: European experience in controlled trials.- Index.